Laminar Pharma ^Company

Laminar Pharma is a pioneering biopharmaceutical company focused on the discovery, rational design, and initial clinical development of a new generation of medicines. They specialize in a novel therapeutic approach called Membrane Lipid Therapy (MLT). Their main goal is to develop MLT-based drugs that can revolutionize the pharmaceutical industry. Laminar Pharma's most promising product, LAM561, is currently in phase III of clinical studies and is expected to be launched in the market by 2025. The company has received recognition for its innovative approach and is actively seeking investors to participate in their capital increase round.